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Abstract
Aims: To assess effects of DF402, a bioisostere of Dimebon/Latrepirdine, on the dis-
ease progression in the transgenic model of amyotrophic lateral sclerosis (ALS) caused 
by expression of pathogenic truncated form of human FUS protein.
Methods: Mice received DF402 from the age of 42 days and the onset of clinical 
signs, the disease duration and animal lifespan were monitored for experimental and 
control animals, and multiple parameters of their gait were assessed throughout the 
pre- symptomatic stage using CatWalk system followed by a bioinformatic analysis. 
RNA- seq was used to compare the spinal cord transcriptomes of wild- type, untreated, 
and DF402- treated FUS transgenic mice.
Results: DF402 delays the onset and slows the progression of pathology. We devel-
oped a CatWalk analysis protocol that allows detection of gait changes in FUS trans-
genic mice and the effect of DF402 on their gait already at early pre- symptomatic 
stage. At this stage, a limited number of genes significantly change expression in 
transgenic mice and for 60% of these genes, DF402 treatment causes the reversion 
of the expression pattern.
Conclusion: DF402 slows down the disease progression in the mouse model of ALS, 
which is consistent with previously reported neuroprotective properties of Dimebon 
and its other bioisosteres. These results suggest that these structures can be consid-
ered as lead compounds for further optimization to obtain novel medicines that might 
be used as components of complex ALS therapy.
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1  |  INTRODUC TION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease 
primarily characterized by dysfunction and death of lower and upper 
motor neurons. There is no cure for this fatal disease, and the effi-
cacy of Riluzole and Edaravone, the only drugs approved for treat-
ment of ALS patients, is very low. Suggested mechanisms of action 
for these two drugs are different; Riluzole is believed to be neuro-
protective because of its ability to block glutamate excitotoxicity, 
whereas Edaravone acts as a scavenger of oxygen radicals (reviewed 
in Refs1,2). A growing number of re- purposed and new drugs as well 
as alternative therapeutic approaches entering clinical trials (for 
recent review, see Refs3,4) raise hope that efficient treatment of 
different forms of familial and sporadic ALS could be achieved by 
designing tailored combinations of traditional pharmacological and 
modern biomedical approaches. Therefore, a search for potential 
components of efficient ALS therapy should include various types 
of potentially neuroprotective drugs, particularly those with pleio-
tropic effects on physiological and pathological processes in the 
nervous system.
In the last decade, gamma- carbolines have attracted attention 
as potential neuroprotectors in the nervous system affected by 
neurodegenerative processes.5– 14 Their neuroprotective activ-
ity can be explained by a combination of multiple mechanisms 
of action described for these compounds.11,15– 28 Irreversible 
pathological aggregation of certain proteins contributes to patho-
genesis of all types of ALS and therefore, it is an obvious target 
for therapeutic intervention. The first gamma- carboline found 
to affect pathological protein aggregation was Dimebon (also 
known as Latrepirdine), originally approved and for many years 
used as an antihistamine drug. An ability of Dimebon to pre-
vent accumulation of cytoplasmic proteinaceous inclusions has 
been first demonstrated in cultured neurons expressing a highly 
aggregation- prone variant of RNA- binding protein TDP- 43.29 
Further studies in various cellular models of proteinopathies con-
firmed anti- aggregation properties of Dimebon and demonstrated 
its ability to activate autophagic mechanism of pathological ag-
gregate elimination.10,11,21,22,27,30 Consistently, chronic treatment 
with Dimebon, when started at a pre- symptomatic stage of the 
disease, delayed the onset of clinical signs, slowed down disease 
progression, and increased animal lifespan in several mouse mod-
els of neurodegeneration, including those that recapitulate key 
features of ALS.7,9,28,31,32 However, the efficacy of Dimebon in 
ameliorating pathology in these models was low and in attempt 
to produce more efficient compounds, several bioisosteres of 
Dimebon have been synthesized. Neuroprotective properties 
have been demonstrated for some of fluorinated bioisosteres in 
mouse models.9,12
Here, we studied effects of one of these bioisosteres, DF402, 
on the disease triggered in transgenic mice by neuron- specific ex-
pression of a highly aggregation- prone truncated form of human 
FUS.33
2  |  MATERIAL S AND METHODS
2.1  |  Animals
Transgenic mice expressing C- terminally truncated form of human 
FUS under control of the neurospecific Thy- 1 regulatory sequences 
(FUS[1– 359]- line 6) have been produced and characterized pre-
viously.33 A line S- FUS[1– 359] produced by backcrossing of the 
original FUS[1– 359] line 6 mice with CD1 mice34,35 was used in the 
current study. Cohorts of experimental animals were formed from 
hemizygous transgenic and wild- type male littermates. Genotyping 
was carried out using a PCR protocol described previously.33 Animals 
were housed in a specific pathogen- free facility with controlled envi-
ronment (temperature 21 ± 2°C, a humidity of 40%– 60%, 12- h light/
dark cycle) and ad libitum access to food and water. Animal work was 
carried out in accordance with the ARRIVE guidelines 2.036 and the 
United Kingdom Animals (Scientific Procedures) Act (1986) and was 
approved by The Bioethics committee of Institute of Physiologically 
Active Compounds, Russian Academy of Sciences (Approval No. 20 
from 23.06.2017).
2.2  |  DF402 treatment and monitoring of the 
disease phenotype
Dimebon bioisostere DF402 (2,8- Dimethyl- 5- [2- (6- trifluoromethyl
pyridin- 3- yl)ethyl]- 2,3,4,5- tetrahydro- 1H- pyrido[4,3- b]indole dihy-
drochloride) was synthesized in IPAC RAS as described elsewhere.37 
Similar to DF302, another fluorine- containing and structurally close 
derivate of Dimebon, that was previously assessed for its ability 
to ameliorate neurodegenerative processes in various models,9,12 
DF402 is water soluble, stable in aqueous solutions, and non- toxic to 
cultured cells and experimental animals. Animals received DF402 in 
the drinking water (70 µg/ml; correspondent to daily dose of 12 mg/
kg/day after adjustment to average daily water intake in these mice) 
from the age of 42 days. The same administration protocol and a 
drug dose were used for assessing the efficacy of Dimebon in our 
previous studies9,31,38 and in two mouse models of neurodegenera-
tion, a slowing down of pathology progression was achieved.9,31 To 
collect data about the disease onset, disease duration, and animal 
lifespan, mice were assessed daily for the development of first signs 
of neuronal pathology (paresis of a limb, unstable gait, hunched pos-
ture, clasping reflex, decreased motility). Observations continued 
after the disease onset and animals were humanely killed when their 
conditions reached the severe level as specified by the Home Office 
Licence.
2.3  |  Animal gait analysis
CatWalk XT system Version 10.6 was used according to the manufac-
turer (Noldus Information Technology, Netherlands) instructions with 
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the Intensity of the Green Walkway Light 16,5 V; Camera Gain 20 dB; 
Green Intensity Threshold 0,1; and Red Ceiling Light 17,7 V. All animals 
had one habituation session to the CatWalk apparatus one day before 
the first test. Each animal was tested every or every second day until 
the onset of clinical signs. On the testing day, each animal was allowed 
to explore and walk freely through the apparatus detection “runway” 
without any rewards. During this test period of maximum 10 minutes, 
at least 3 videos of an uninterrupted crossing of the recording field 
of the runway (approximately 35 cm) were automatically recorded. 
Runs for analysis were selected based on a minimum of four step cy-
cles in the crossing field, such that each step cycle involved capturing 
the use of each of the four paws irrespective of the order in which 
paws were used. After classification of the footprints in these runs 
using the CatWalk software, qualified data39– 41 were exported for 
further analysis to the RStudio.42 Given that the disease progression 
has individual characteristics resulting in a floating date of the mani-
festation of clinical signs, we have compared changes in the gait of 
animals in the reverse direction starting from the day when first clini-
cal signs were observed to the day of the beginning of data collection. 
In order to combine the data of gait analysis between the animals 
with different ages, time intervals were adjusted to 25 days for each 
animal starting from the day of the manifestation of clinical signs, as 
illustrated in Figure S1. Statistical analysis was done using nonpara-
metric Wilcoxon test for each of CatWalk parameters of untreated 
and DF402- treated mice. The difference was considered significant 
if it was determined in at least one of the time intervals: 1– 10 days, 
11– 18 days, and 19– 25 days with p < 0.05 (Benjamini- Hochberg cor-
rection). Representative analysis of significantly changed group of 
variables was performed by calculating the frequency of compo-
nents implemented in the intrinsic structure of CatWalk parameters. 
For example, parameter “Right_Hind_MaxIntensity” consists of two 
components “Right_hind” and “MaxIntensity” representing qualita-
tive and quantitative indicators. The frequency was determined as a 
ratio of the significantly changed parameters or components included 
in such parameter (p < 0.05; Benjamini- Hochberg correction) to all 
CatWalk parameters. For principal component analysis, the values of 
all parameters were transformed to z- scores ((x- mean(x)/sd(x)). The 
multivariate analysis of variance43 was used to find traits with sig-
nificant changes between experimental groups. Classical (Torgerson) 
multidimensional scaling (MDS)44 was performed to estimate clus-
terization between mice groups. Visualization was performed using 
custom scripts written in R.
2.4  |  RNA sequencing
For RNA- seq analysis, total RNA was extracted from the tho-
racic and lumbar spinal cords of experimental and control pre- 
symptomatic mice (70- day- old, 4 animals per group) using Qiagen 
RNeasy Plus mini kit. RNA quantification, quality controls, and fur-
ther steps were performed as described previously.34 Briefly, cDNA 
libraries for the dual indexed single- end sequence analysis were pre-
pared from equal amounts (270 ng) of each total RNA sample using 
Illumina TruSeq Stranded Total RNA LT Sample Prep Kit. Following 
quality checks and normalization, cDNA libraries were sequenced on 
Illumina NextSeq 500 to generate single- end 75 bp reads.
Raw sequence data processing (QC, trimming, alignment, read 
quantification) was performed with PPLine tool.45 Differential gene 
expression analysis was performed with the edgeR package.46 Gene 
Ontology and KEGG enrichment analyses were performed using 
topGO (v.2.36.0) and clusterProfiler packages.47 Multidimensional 
scaling (MDS) between all experimental samples was performed 
with limma package.48
Sorting of microglial and neuronal genes of the whole spinal cord 
samples was performed as described previously.34,49
Compensation coefficient of DF- 402 treatment on FUS- mediated 
transcriptomic changes was calculated as a percentage of [mean(log-
CPM)S- FUS[1– 359] — mean(logCPM)S- FUS[1– 359]+DF402)] / 
[mean(logCPM)S- FUS[1– 359] — mean(logCPM)WT]. Density distri-
bution of compensated genes was estimated using Kernel Density 
Estimation (KDE).
Visualization of gene set enrichment analysis (GSEA) was per-
formed using custom scripts written in Python and R. Raw data of 
RNA- seq for untreated and DF402- treated S- FUS[1– 359] mice were 
deposited in NCBI GEO database under the number GSE16 1680. 
RNA- seq data of wild- type animals were deposited previously by 
the number GSE13 0604.
The real- time RT- qPCR analysis of mRNA expression was carried 
out as described previously.34,50
2.5  |  General statistical analysis
Data sets for the disease onset, disease duration, animal lifespan, 
and RT- qPCR analysis of RNA expression were assessed for normal 
distribution and for those that passed D'Agostino and Pearson test, 
statistical significance of observed difference was evaluated by one- 
way ANOVA or paired t- test, as appropriate. For not normally dis-
tributed data, Kruskal- Wallis ANOVA and/or Mann- Whitney U- test 
were used.
3  |  RESULTS
3.1  |  Chronic treatment with DF402 delays onset 
and prolongs duration of the disease in transgenic 
mice expressing C- terminally truncated form of 
human FUS
Male S- FUS[1– 359] transgenic mice received DF402, a bioisostere 
of Dimebon, as described in Materials and Methods. The treatment 
started soon after weaning, from 42 days of age, which allows at 
least 7 weeks of drug administration before the earliest onset of 
pathology observed for this transgenic line. Animals treated with 
DF402 and their control male littermates were checked daily for 
the presence of discernible clinical signs of the disease. The age of 
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the disease onset denoted by the first manifestation of clinical signs 
was recorded, and monitoring of animal health was continued until 
their conditions deteriorated to the level when they were deemed 
to be premorbid and therefore were euthanized by a Schedule 1 
method. We found that chronic DF402 treatment increases animal 
lifespan by 13% (Figure 1A,D), which was due to both a later onset 
(Figure 1B) and longer duration (Figure 1C) of the disease (by 11% 
and 24%, respectively).
3.2  |  CatWalk analysis of the gait of transgenic 
mice expressing C- terminally truncated form of human 
FUS detects impairments of motor function and 
effects of DF402 at pre- symptomatic stage
To assess whether instrumental analysis of multiple parameters 
of animal gate would allow detecting the decline of animal motor 
performance long before obvious manifestation of clinical signs 
and revealing any improvements of this performance as the result 
of DF402 treatment, we used CatWalk XT system to systematically 
monitor gait of DF402- treated and control, untreated S- FUS[1– 359] 
transgenic mice as well as their wild- type littermates. For this part of 
the study, additional cohorts of 24 wild- type and 49 S- FUS[1– 359] 
transgenic male littermate mice were produced. The same as above 
protocol of DF402 administration was used to treat 25 of these S- 
FUS[1– 359] mice from the age of 42 days. Four weeks later, that is, at 
the age of 70 days, four animals from each group were humanely eu-
thanized and tissue samples were collected for transcriptomic analy-
sis (see below). It is important to note that at this age, all transgenic 
animals were undistinguishable from their wild- type littermates and 
in this cohort of S- FUS[1– 359] mice, a mean age of the disease onset 
was 124 days for untreated and 137 days for DF402- treated animals. 
However, the CatWalk analysis of 177 gait parameters carried out as 
described in Materials and Methods revealed differences between 
groups already at the age of 70 days: 128 parameters were found dif-
ferent between untreated S- FUS[1– 359] and wild- type mice and 16 
parameters— between untreated and DF402- treated S- FUS[1– 359] 
mice (Figure 2). The latter two groups of mice have continued to be 
regularly assessed on the CatWalk until the first day of the disease 
onset denoted by the manifestation of clinical signs. Because the 
timing of the disease onset varies substantially between individual 
S- FUS[1– 359] mice, we analyzed changes in their gait in the reverse 
F I G U R E  1  Effect of DF402 on the 
disease parameters in S- FUS[1– 359] 
transgenic mice. Experimental group of 
hemizygous FUS transgenic mice received 
DF402 in drinking water (70 μg/ml) from 
the age of 42 days. Kaplan- Meier plot of 
animal survival in cohorts of hemizygous 
control (red circles, n = 40) and DF402- 
treated (green squares, n = 32) littermate 
FUS transgenic mice. Log- rank test 
revealed significant difference between 
survival curves, p = 0.0214 (A). Bar charts 
show means ± SEM and unpaired t- test 
for the disease onset (B, *p = 0.0371), 
disease duration (C, *p = 0.0175), and 
animal lifespan (D, *p = 0.0146) in cohorts 
of control (n = 40) and DF402- treated 
(n = 32) mice
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direction from the actual day of the onset as illustrated in Figure S1. 
We considered the time interval of 25 days as the pre- symptomatic 
stage for all of the studied animals. This pre- symptomatic stage was 
subdivided into three dynamic ranges: 1) 25– 15 days (early stage), 2) 
14– 8 days (middle stage), and 3) 7– 1 day (late stage) to the day when 
discernible clinical signs were first detected.
The comparative analysis of the gait between DF402- treated 
and untreated S- FUS[1– 359] transgenic mice revealed 31 parame-
ters that display significant changes at one, two, or all three sub-
stages of the pre- symptomatic stage: 8 parameters at the early 
stage, 19 at the middle stage, and 16 at the late pre- symptomatic 
stage (Figure 3A). Most of the parameters affected by the DF402 
treatment at the pre- symptomatic stage attribute to the indicators 
of front and hind limb movements, including stride length and width, 
and the intensity of paws pressure rather than indicators of the gen-
eral body movements, like speed or running cadence (Figure 3B). We 
also noted that the values for most gait parameters that displayed 
statistically significant changes appeared to be decreased after the 
DF402 treatment (log2 fold change from −0.5 to −0.05, p < 0.05, 
Wilcoxon test, BH corrected) (Figure 3C).
3.3  |  Expression of a number of genes in the spinal 
cords of transgenic mice expressing C- terminally 
truncated form of human FUS is already changed at 
pre- symptomatic stage and treatment with DF402 
reverts expression of more than a half of these genes
In an attempt to reveal molecular processes and mechanisms that 
are affected by chronic DF402 treatment and might be involved in 
the delay of the disease onset in S- FUS[1– 359] transgenic mice, we 
compared spinal cord transcriptomes of 70- day- old untreated and 
DF402- treated transgenic mice. At this pre- symptomatic stage, no 
neurodegenerative changes (eg, neuronal loss or neuroinflammation) 
that significantly affect expression pattern at the symptomatic stage 
are present in the spinal cord of S- FUS[1– 359] mice.33 However, 
certain functional changes can be already detected at this age by 
comparing CatWalk gait analysis data for transgenic and wild- type 
littermate mice (Figure 2A,B); moreover, such analysis can reveal dif-
ferences between untreated and DF402- treated mice (Figure 2C).
cDNA libraries for RNA- seq were prepared from the spinal cord 
samples of four animals per genotype/treatment group and as a result 
of deep sequencing, we obtained ~15 million reads for each library. 
Differential gene expression analysis revealed relatively modest 
changes (37 differentially expressed genes (DEG) with LogCPM >2, 
FDR <0.05) in the transcriptome of S- FUS[1– 359] mice compared to 
the transcriptome of age- matched wild- type littermates, while tran-
scriptome of DF402- treated S- FUS[1– 359] mice showed more such 
changes (171 DEG with LogCPM >2, FDR <0.05) and can be clearly 
distinguished on multidimensional scaling (Figure S2A, Table S1). To 
discriminate neuron- specific and microglia- specific genes among the 
identified DEG, we used previously published data sets of purified 
microglia and laser- microdissected ventral horns of the mouse spi-
nal cord.51,52 Between all identified DEG, 64% belonged to genes 
with exclusive or predominant expression in neurons and only 6%— 
to genes with expression intrinsic to microglial cells of the mouse 
spinal cord, while other 30% of DEG were common for both types of 
cells and were considered as shared (Figure S2B). Thus, at the pre- 
symptomatic stage the observed gene expression changes in the spi-
nal cord take place predominantly in neurons.
When changes in gene expression between S- FUS[1– 359] and 
wild- type groups were compared with changes in gene expression 
F I G U R E  2  Clusterization of experimental mice at the age of 70 days using CatWalk data analysis and sorting of statistical differences in 
changes of gate parameters. (A) Results of classical (Torgerson) MDS analysis are shown. Each dot represents an experimental animal: blue 
for WT mice, red for untreated S- FUS[1– 359] mice, and green for DF402- treated S- FUS[1– 359] mice. Total fraction of variance explained 
by principal components 1 (x- axis) and 2 (y- axis) was 47.3%. (B) Volcano plot illustrates the number of parameters that display significant 
changes between WT and S- FUS[1– 359] mice. Black line on y- axis represents threshold of significant changes of parameters (−log10(0.05)). 
Red and black dots represent parameters with and without statistically significant changes, respectively. (C) Volcano plot illustrates the 
number of parameters that display significant changes between untreated and DF402- treated S- FUS[1– 359] mice. Black line on y- axis 
represents threshold of significant changes of parameters (−log10(0.05)). Green and black dots represent parameters with and without 
statistically significant changes, respectively
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F I G U R E  3  Comparative analysis of the gait changes at the pre- symptomatic stage between untreated and DF402- treated S- FUS[1– 359] 
mice. CatWalk XT system was used to measure gait parameters during the pre- symptomatic stage subdivided into three intervals (from 
25 to 15, 14 to 8, and 7 to 1 days) as explained in the Material and Methods and Results sections and illustrated in Figure S1. (A) The Venn 
diagram shows the number of gait parameters that display statistically significant changes at three substages of the pre- symptomatic 
stage as the result of DF402 treatment. (B) The graph illustrates frequency of occurrence of variables exhibiting significant changes for the 
studied transgenic animals at any of three intervals of the pre- symptomatic stage. The size of each bubble indicates a number of variables 
for a particular qualitative and quantitative indicator, for example, limb or intensity. Enrichment score was calculated following equation 
log2(freq_significant / freq_overall), where freq_significant— frequency of the parameter among the list of significantly changed parameters, 
and freq_overall— frequency of the parameter among the general list of the parameters. Parameters with enrichment score lower than 0 
were discarded. (C) Log2 fold change of gait parameters between untreated and DF402- treated S- FUS[1– 359] mice separately for early, 
middle, and late intervals of the pre- symptomatic stage. Gray zone represents insignificant changes
F I G U R E  4  Compensation of FUS- mediated transcriptomic changes by DF402 treatment. (A) Comparison of log2 fold change for genes 
that show difference in expression levels between S- FUS[1– 359] and WT transcriptomes (x- axis), and between S- FUS[1– 359] and S- FUS[1– 
359]+DF402 transcriptomes (y- axis). Positive values correspond to activation in transgenic mice or under treatment. One point represents 
one gene, and only genes exhibiting significant changes (FDR <0.05) are shown. Genes that display difference between S- FUS[1– 359] 
and WT transcriptomes are shown in red, and those that display difference only between S- FUS[1– 359]+DF- 402 and S- FUS[1– 359] 
transcriptomes— in black. (B) Dependence of compensation coefficient (y- axis) on log2 fold change in the S- FUS[1– 359] vs WT comparison 
(x- axis). Compensation coefficient was calculated as a percentage of [mean(logCPM)S- FUS[1– 359] — mean(logCPM)S- FUS[1– 359]+DF402)] 
/ [mean(logCPM)S- FUS[1– 359] — mean(logCPM)WT]. (C) Heatmap of differentially expressed genes between groups S- FUS[1– 359] vs WT 
and S- FUS[1– 359] vs S- FUS[1– 359]+DF- 402. The expression values of the genes are Z- transformed. Products of the transgene cassette 
expression, Fus and Thy1, that were not used in analysis of compensation shown in panels a and b, are still included in the heatmap with 
gene names shown in red
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between S- FUS[1– 359] and DF402- treated S- FUS[1– 359] groups, 
we found negative correlations of log2 fold changes (Spearman cor-
relation = −0.55, p < 0.05) with over 80% of DEG exhibit opposite 
directions of expression changes (Figure 4A). Such pattern of gene 
expression changes might indicate that DF402 administration allevi-
ates the effect of FUS transgene expression in the motor neurons. 
To quantify the compensation effect mediated by DF- 402 treat-
ment, we calculated the compensation coefficient as described in 
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the Materials and Methods section. According to the formula used 
for calculations, the coefficient near 100% means almost complete 
compensation by treatment, higher values correspond to over-
compensation and negative values correspond to cases where the 
treatment enhances the S- FUS[1– 359] phenotype. Applying this ap-
proach, we show that a large fraction of DEG observed in the com-
parison of S- FUS[1– 359] and wild- type samples have undergone the 
compensation in their expression levels (compensation coefficient 
between 40 and 100 for 60% of DEG), indicating that DF- 402 treat-
ment substantially ameliorates the gene expression changes induced 
by FUS transgene expression in the spinal cord neurons (Figure 4B, 
Figure S3). Interestingly, the compensation applies to many genes 
upregulated in the presence of pathogenic FUS protein, resulting in 
the reversion of expression toward lower levels typical for expres-
sion of these genes in the spinal cord of wild- type animals (lower 
cluster in Figure 4C, Figure S4A- D). In contrast, genes that were 
downregulated in the spinal cord of transgenic mice showed less 
compensation (upper cluster in Figure 4C, Figure S4E). Genes from 
the middle cluster in Figure 4C showed no compensation or even a 
trend toward overcompensation (Figure S4F,G).
4  |  CONCLUSIONS
4.1  |  Multifactorial analysis of CatWalk testing 
results detects gait changes in FUS transgenic mice at 
early pre- symptomatic stage
CatWalk is an effective combination of hardware and software in an 
experimental system designed for simultaneous analysis of multiple 
parameters of rodent gait.53,54 It has been successfully used to as-
sess changes in animal motor function in several transgenic models 
of neurodegenerative diseases.55– 58 Here, this system was used for 
the first time to detect motor deficiency in transgenic mice modeling 
ALS- FUS by neuronal expression of pathogenic truncated form of 
human FUS protein.33
Our analysis of parameters obtained by CatWalk testing of co-
horts of transgenic and wild- type littermate mice allowed detecting 
gait changes in S- FUS[1– 359] mice already at early pre- symptomatic 
stage, that is, long before manifestation of obvious clinical signs 
of the disease. This paves way for developing a protocol for ac-
curate prediction of the time of the disease onset in an individual 
S- FUS[1– 359] mouse at least a week in advance, which can be con-
sidered as an equivalent of the detection of very early ALS symptoms 
in human patients. Such protocol, which currently goes through final 
stages of testing in our laboratories, will permit normalizing start of 
a drug and placebo administration at pre- symptomatic stage within 
a cohort of experimental and control S- FUS[1– 359] mice used for 
preclinical trials.
By comparing data obtained in longitudinal studies of the 
CatWalk performance of control and DF402- treated S- FUS[1– 359] 
mice, we demonstrated that a multifactorial analysis of gait param-
eters used in this study is sufficiently robust to detect and monitor 
even mild effects of drugs or other therapeutic interventions from 
the early stage of motor neuron disease in this transgenic model. 
Therefore, the algorithm of the CatWalk analysis developed in this 
study is a powerful tool for accurate assessment of the development 
of motor dysfunction in mice.
4.2  |  DF402, a bioisostere of Dimebon, ameliorates 
pathology in FUS transgenic mice
We have found that chronic treatment with DF402, a bioisostere of 
Dimebon, an over- the- counter drug that demonstrated a mild abil-
ity to suppress pathological changes in several models of neurode-
generative diseases, slowed down the development and progression 
of the disease in S- FUS[1– 359] mice with a statistically significant 
prolongation effect observed on all three main parameters, namely 
time to the disease onset (+11%), disease duration (+24%), and animal 
lifespan (+13%). Although it is difficult to directly compare results of 
studies that used different experimental setups and endpoints, the 
efficacy of chronic administration of a low dose of DF402 via drink-
ing water is comparable and possibly higher than the efficacy of a 
similar protocol of chronic Riluzole administration to S- FUS[1– 359] 
mice.59– 61 It should be also noted that chronic administration of 
Dimebon showed a delayed onset of clinical signs and an increase 
in lifespan of SOD1(G93A) mouse model of ALS,28 whereas the ef-
ficacy of Riluzole in this model was negligible.62 Two other bioisos-
teres of Dimebon, DF302 and DF312, have also been found capable 
to ameliorate disease parameters but not to prevent the develop-
ment and progression of neuropathology in mouse models.9,12 Taken 
together, these results suggest that these structures can be consid-
ered as promising lead compounds for further optimization to ob-
tain novel medicines that might be used in combination with other 
drugs or therapeutic approaches to achieve efficient treatment of 
ALS patients.
4.3  |  Gene expression changes take place in the 
spinal cord of S- FUS[1– 359] mice already at early pre- 
symptomatic stage
Two key mechanisms are involved in molecular pathogenesis of 
ALS- FUS, namely impairments in RNA metabolism and pathologi-
cal aggregation of FUS. Because C- terminally truncated FUS 1– 359 
protein lacks major RNA- binding domains,63– 66 its expression in the 
nervous system of transgenic mice cannot have direct effect on 
RNA metabolism. Therefore, S- FUS[1– 359] mice represent a model 
of pathology triggered solely by FUS aggregation and changes in the 
nervous system transcriptome of these mice reflect the develop-
ment of FUSopathy- induced pathology.
We found that changes in expression pattern for a limited num-
ber of genes in the spinal cord of S- FUS[1– 359] mice compared to 
wild- type littermates happen long before transgenic mice develop 
first clinical signs of pathology. Because the expression of pathogenic 
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FUS in S- FUS[1– 359] mice is neuron- specific, we expected that at 
the pre- symptomatic stage, that is, before any neuroinflammatory 
responses are developed, most of gene expression changes will 
be restricted to neurons. Our bioinformatic analysis demonstrated 
that at this stage, most DEG indeed belong to genes expressed in 
neurons.
4.4  |  Treatment with DF402 reverses 
changes of expression of many genes affected at the 
pre- symptomatic stage of the pathology development 
in S- FUS[1– 359] mice
Bioinformatic analysis of RNA- seq data also revealed that DF402 
treatment affects spinal cord transcriptomes of S- FUS[1– 359] mice. 
It also demonstrated that genes differentially expressed in the spinal 
cord of S- FUS[1– 359] compared to wild- type mice can be divided 
into two principal groups: those that undergo substantial reversion 
of their expression by DF402 treatment of S- FUS[1– 359] mice and 
those that display no or very little changes following DF402 treat-
ment. As DF402 only slows down but cannot prevent the develop-
ment of pathology, it is feasible to suggest that DEG belonging to 
the first group, DF402- revertants, represent a group of genes and 
encoded proteins that have only marginal effect on the neurode-
generation in this model system. In contrast, genes belonging to the 
second group and their encoded proteins might play more substan-
tial role in the progression of pathological changes from the pre- 
symptomatic to symptomatic stage and therefore constitute more 
credible molecular targets for therapeutic intervention, at least in 
ALS- FUS cases. Testing these suggestions will require further analy-
sis of the observed mRNA changes, confirmation that they correlate 
with changes in the encoded protein levels, and detailed studies of 
the effects of modulation of each identified gene expression on the 
development of proteinopathy- induced neurodegeneration in vari-
ous experimental systems, all of which are beyond the scope of the 
current report.
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